FTSE MIB
33.629,21 -107,19 (-0,32%) Dow Jones
38.675,68 +450,02 (+1,18%) Nasdaq
16.156,33 +315,37 (+1,99%) Nikkei 225
38.236,07 -37,98 (-0,10%) Petrolio
77,99 -0,96 (-1,22%) Bitcoin EUR
58.569,54 +3.569,59 (+6,49%)
Nyxoah S.A. (NYXH.BR)
| Chiusura precedente | 9,18 |
| Aperto | 9,20 |
| Denaro | N/D x N/D |
| Lettera | N/D x N/D |
| Min-Max giorno | 9,12 - 9,52 |
| Intervallo di 52 settimane | 3,79 - 17,60 |
| Volume | |
| Media Volume | 49.838 |
| Capitalizzazione | 269,616M |
| Beta (5 anni mensile) | 0,48 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -1,58 |
| Prossima data utili | 14 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 15,30 |
GlobeNewswireNyxoah Announces Partnership with ResMed in Germany
Nyxoah Announces Partnership with ResMed in GermanyCreates a continuum of care in the German obstructive sleep apnea market Mont-Saint-Guibert, Belgium – September 28, 2023, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company has entered into a partnership with ResMed Germany to
- GlobeNewswire
Nyxoah to Participate in the Cantor Fitzgerald Global Healthcare Conference
Nyxoah to Participate in the Cantor Fitzgerald Global Healthcare Conference Mont-Saint-Guibert, Belgium – September 12, 2023, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will participate in the Cantor Fitzgerald Global Healthcare Conference, which takes place September 2
- GlobeNewswire
Nyxoah to Participate in Upcoming Investor Conferences
Nyxoah to Participate in Upcoming Investor Conferences Mont-Saint-Guibert, Belgium – September 5, 2023, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will participate in two upcoming investor conferences in New York City. Olivier Taelman, Nyxoah’s Chief Executive Officer,
